


# Imagenomix brings EGFR mutation prediction from routine H&E slides to Techcyte Fusion AP

*Pulmogene-Predict lets pathologists explore molecular signals digitally in research and trial work without using additional tissue*

OREM, UT, UNITED STATES, October 13, 2026 /EINPresswire.com/ -- [Techcyte](#), developer of Fusion, the enterprise digital pathology platform, today announced that it is integrating Pulmogene-Predict from [Imagenomix](#) into Fusion AP. Pulmogene-Predict is the lung cancer application within the Imagenomix IGX Predict platform. The integration starts with EGFR mutation prediction for research, translational, and clinical trial enrichment use and future expansion to other biomarkers, including KRAS, TP53, and more.



The integration is designed to let pathologists send routine hematoxylin and eosin (H&E) whole-slide images from a Fusion AP case to Imagenomix's cloud for analysis. Results return to the Fusion case as a mutation score, a spatial heatmap showing where in the tissue the biomarker signal is strongest, and a PDF prediction report. Because Pulmogene-Predict works from existing images, it needs no additional stains or sections, preserving limited biopsy material for confirmatory testing.

In lung cancer, the molecular question usually leaves the pathologist's hands once the H&E is read. Tissue goes out for sequencing, which is slow, costly, and consumes tissue a small biopsy may not have enough to spare. As a result, many patients never get tested at all. Pulmogene-Predict closes this access gap. It lets the pathologist see the tumor's mutation profile from the H&E during their initial review.

Pulmogene-Predict supports a screen-then-confirm research approach. It can also screen archived H&E slides to identify potential biomarker-positive cohorts, supporting trial enrichment and discovery without consuming additional tissue.

“Pathologists already have the H&E slide in front of them,” said Ben Cahoon, CEO of Techcyte. “With Pulmogene-Predict in Fusion AP, they can look at likely genotypes from that same slide for research and trial work, while also making the reflex NGS workflow more efficient.”

“We developed the IGX Predict product family to explore molecular information from the H&E slides labs already have, without consuming any tissue,” said Travis Wold, CEO at Imagenomix. “Working with Techcyte brings that capability into an established slide review workflow, starting with EGFR mutation prediction in lung cancer.”

Pulmogene-Predict is intended for research, translational, and trial-enrichment use. It is not a clinical diagnostic and does not replace next-generation sequencing (NGS) or immunohistochemistry (IHC). Techcyte Fusion AP is for Research Use Only in the United States and is not for diagnostic use.

Visit Techcyte at Booth 410 during [Pathology Visions](#), October 16–18 in San Diego, to meet the teams and learn how the integration will support molecular prediction research within Fusion AP.

###

#### About Imagenomix

Imagenomix predicts cancer genetics directly from routine pathology images using AI. Its platform identifies actionable variants from standard H&E slides with a rapid turnaround, at a fraction of the cost of next-generation sequencing, and without consuming additional tissue. Imagenomix works with pathology practices and biopharma partners to reach the genomically underserved patients who may never receive molecular testing. Learn more at [imagenomix.ai](https://imagenomix.ai). Pulmogene-Predict is for Research Use Only.

#### About Techcyte

Techcyte is transforming the practice of pathology through an enterprise digital pathology platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab.

By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment.

Visit [techcyte.com](https://techcyte.com) for more information.

Techcyte Fusion is for Research Use Only in the United States.

Troy Bankhead

Techcyte

+1 435-210-6200

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/948251165>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.